C9ORF72: What It Is, What It Does, and Why It Matters

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• The C9ORF72 gene mutation is the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
• The mutation leads to both loss-of-function (haploinsufficiency) and gain-of-function effects, including RNA and dipeptide repeat protein aggregation.

Purpose of the Study:

• To review current knowledge on the C9ORF72 protein and its role in FTD and ALS.
• To explore the contribution of C9ORF72 haploinsufficiency to disease pathogenesis.
• To inform the development of refined therapeutic strategies.

Main Methods:

• Review of existing literature on C9ORF72 gene mutations, protein function, and disease mechanisms.
• Analysis of findings from cellular and animal models of C9ORF72-related disorders.
• Examination of patient data and recent research on C9ORF72 haploinsufficiency.

Main Results:

• The toxicity of gain-of-function products (aggregating RNAs and dipeptide repeat proteins) is well-established, with ongoing therapeutic development.
• Emerging evidence increasingly points to the significant contribution of C9ORF72 protein loss-of-function (haploinsufficiency) to disease.
• Recent findings provide a clearer understanding of how reduced C9ORF72 protein levels impact disease progression.

Conclusions:

• Therapeutic strategies for C9ORF72-related FTD and ALS should consider both gain-of-function and loss-of-function mechanisms.
• Compensating for decreased C9ORF72 protein levels or preventing further reduction may be crucial for effective treatment.
• A comprehensive approach targeting both toxic products and protein deficiency is needed for future therapies.